Roche To Acquire Immuno-Oncology Company Tusk Therapeutics in $759-Million DealBy
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million). Tusk has developed an antibody with a mode of action aimed at depleting regulatory T-cells (Tregs), which suppress immune responses, including those against cancer cells.
Tusk’s antibody has been designed to deplete harmful Tregs while not interfering with other immune cells acting against the tumor. Tusk’s program is expected to start clinical trials in cancer patients toward the end of 2019.
Under the agreement, Tusk’s shareholders will receive an upfront cash payment of EUR 70 million ($80 million) plus additional contingent payments of up to EUR 585 million ($675 million) based on achievements of certain predetermined milestones.
Tusk was founded in 2014 by Droia Oncology Ventures, Tusk’s majority shareholder.
Source: Tusk Therapeutics